Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2016 Apr 13;16(4):545–554. doi: 10.3233/CBM-160596

Higher circulating levels of chemokine CXCL10 in patients with breast cancer: Evaluation of the influences of tumor stage and chemokine gene polymorphism

A Jafarzadeh a,b,*, H Fooladseresht c, M Nemati b, Z Assadollahi d, A Sheikhi e, A Ghaderi c,f
PMCID: PMC13016515  PMID: 27002757

Abstract

BACKGROUND:

The CXCL10 receptor, CXCR3, is preferentially expressed on Th1 and NK cells. Therefore, CXCL10 acts as a chemoattractant for these cells.

OBJECTIVE:

The aim was to evaluate the CXCL10 levels and a single nucleotide polymorphism (SNP), rs4508917, in chemokine gene, in patients with breast cancer (BC).

METHODS:

A total of 200 subjects including 100 women with BC and 100 healthy women were enrolled into study. The serum CXCL10 levels were measured by ELISA and the SNP rs4508917 was determined by polymerase chain reaction-restriction length polymorphism (PCR-RFLP).

RESULTS:

The CXCL10 levels were significantly higher in patients than control group (P< 0.0001). There was also significant difference between tumor stages regarding the CXCL10 levels (P< 0.0001). The frequencies of GG genotype and G allele at rs4508917 were significantly higher in patients than controls (P< 0.0001). The CXCL10 levels were higher in patients with GG genotype whereas they were lower in healthy subjects having GG genotype as compared with those having AA genotype at rs4508917 (P< 0.001).

CONCLUSION:

Higher CXCL10 levels in patients with BC represent that the chemokine may contributes in tumor development. The rs4508917 may play a role in the susceptibility to BC. Different association was also observed between rs4508917 and CXCL10 levels in patients with BC and healthy subjects.

Keywords: Breast cancer, chemokine, CXCL10, gene polymorphism, rs4508917

Full Text

The Full Text of this article is available as a PDF (301.4 KB).

References

  • [1]. Siegel R., Naishadham D., and Jemal A.. Cancer statistics, 2013. CA Cancer J Clin. 63 (2013), 11-30. [DOI] [PubMed] [Google Scholar]
  • [2]. Palacios-Arreola M.I., Nava-Castro K.E., Castro J.I., Garcia-Zepeda E., Carrero J.C., and Morales-Montor J.. The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. Journal of Immunology Research. 2014 (2014), 849720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3]. Park N.J. and Kang D.H.. Breast cancer risk and immune responses in healthy women. Oncology Nursing Forum. 33 (2006), 1151-1159. [DOI] [PubMed] [Google Scholar]
  • [4]. Kees T. and Egeblad M.. Innate immune cells in breast cancer-from villains to heroes? Journal of Mammary Gland Biology and Neoplasia. 16 (2011), 189-203. [DOI] [PubMed] [Google Scholar]
  • [5]. Gruber I., Landenberger N., Staebler A., Hahn M., Wallwiener D., and Fehm T.. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Research. 33 (2013), 2233-2238. [PubMed] [Google Scholar]
  • [6]. Zhu J. and Paul W.E.. Heterogeneity and plasticity of T helper cells. Cell Research. 20 (2010), 4-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7]. Faghih Z., Erfani N., Haghshenas M.R., Safaei A., Talei A.R., and Ghaderi A.. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunology Letters. 158 (2014), 57-65. [DOI] [PubMed] [Google Scholar]
  • [8]. Kennedy R. and Celis E.. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunology Reviews. 222 (2008), 129-144. [DOI] [PubMed] [Google Scholar]
  • [9]. Lee H.J., Song I.C., Yun H.J., Jo D.Y., and Kim S.. CXC chemokines and chemokine receptors in gastric cancer: From basic findings towards therapeutic targeting. World Journal Gastroenterology. 20 (2014), 1681-1693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10]. Zhu Q., Han X., Peng J., Qin H., and Wang Y.. The role of CXC chemokines and their receptors in the progression and treatment of tumors. Journal of Mololecular Histology. 43 (2012), 699-713. [DOI] [PubMed] [Google Scholar]
  • [11]. Vandercappellen J., Van Damme J., and Struyf S.. The role of CXC chemokines and their receptors in cancer. Cancer Letters. 267 (2008), 226-244. [DOI] [PubMed] [Google Scholar]
  • [12]. Viola A., Sarukhan A., Bronte V., and Molon B.. The pros and cons of chemokines in tumor immunology. Trends in Immunology. 33 (2012), 496-504. [DOI] [PubMed] [Google Scholar]
  • [13]. Franciszkiewicz K., Boissonnas A., Boutet M., Combadiere C., and Mami-Chouaib F.. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Research. 72 (2012), 6325-6332. [DOI] [PubMed] [Google Scholar]
  • [14]. Antonelli A., Ferrari S.M., Giuggioli D., Ferrannini E., Ferri C., and Fallahi P.. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmune Reviews. 13 (2014), 272-280. [DOI] [PubMed] [Google Scholar]
  • [15]. Liu M., Guo S., Hibbert J.M., Jain V., Singh N., Wilson N.O., and Stiles J.K.. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22 (2011), 121-130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16]. Mulligan A.M., Raitman I., Feeley L., Pinnaduwage D., Nguyen L.T., O'Malley F.P., Ohashi P.S., and Andrulis I.L.. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clinical Cancer Research. 19 (2013), 336-346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17]. Chaturvedi P., Gilkes D.M., Wong C.C., Kshitiz L.W., Zhang H., Wei H., Takano N., Schito L., Levchenko A., and Semenza G.L.. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. The Journal of Clinical Investigation. 123 (2013), 189-205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18]. Wenzel J., Bekisch B., Uerlich M., Haller O., Bieber T., and Tuting T.. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. American Journal of Clinical Pathology. 124 (2005), 37-48. [DOI] [PubMed] [Google Scholar]
  • [19]. Tahmasebi Z., Akbarian M., Mirkazemi S., Shahlaee A., Alizadeh Z., Amirzargar A.A., Jamshidi A.R., Ghoroghi S., Poursani S., and Nourijelyani K.. Interleukin-1 gene cluster and IL-1 receptor polymorphisms in Iranian patients with systemic lupus erythematosus. Rheumatology international. 33 (2013), 2591-2596. [DOI] [PubMed] [Google Scholar]
  • [20]. Sugimoto M., Yamaoka Y., and Furuta T.. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World Journal Gastroenterology. 16 (2010), 1188-1200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21]. Guergnonand J. and Combadiere C.. Role of chemokines polymorphisms in diseases. Immunology Letters. 145 (2012), 15-22. [DOI] [PubMed] [Google Scholar]
  • [22]. Kotrych D., Dziedziejko V., Safranow K., Drozdzik M., and Pawlik A.. CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis. Rheumatol Int. 35 (2015), 1319-1323. [DOI] [PubMed] [Google Scholar]
  • [23]. Xu Z., Liu Y., Liu L., Li X., Bai S., Rong Y., Wang H., Mao Y., Xin S., and Xu D.. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population. PLoS One. 8 (2013), e72799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24]. Wilson N., Driss A., Solomon W., Dickinson-Copeland C., Salifu H., Jain V., Singh N., and Stiles J.. CXCL10 gene promoter polymorphism -1447A>G correlates with plasma CXCL10 levels and is associated with male susceptibility to cerebral malaria. PLoS One. 8 (2013), e81329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25]. Azad A.K., Sadee W., and Schlesinger L.S.. Innate immune gene polymorphisms in tuberculosis. Infection and Immunity. 80 (2012), 3343-3359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26]. Bruck P., Bartsch W., Penna-Martinez M., Kahles H., Seidl C., Bohme A., Badenhoop K., and Ramos-Lopez E.. Polymorphisms of CXCR3-binding chemokines in type 1 diabetes. Human Immunology. 70 (2009), 552-555. [DOI] [PubMed] [Google Scholar]
  • [27]. Galimberti D., Scalabrini D., Fenoglio C., Comi C., De Riz M., Venturelli E., Lovati C., Mariani C., Monaco F., and Bresolin N.. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. European Journal of Neurology. 14 (2007), 162-167. [DOI] [PubMed] [Google Scholar]
  • [28]. Tang N.L.S., Fan H.P.Y., Chang K.C., Ching J.K.L., Kong K.P.S., Yew W.W., Kam K.M., Leung C.C., Tam C.M., and Blackwell J.. Genetic association between a chemokine gene CXCL-10 (IP-10, interferon gamma inducible protein 10) and susceptibility to tuberculosis. Clinica Chimica Acta. 406 (2009), 98-102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29]. Lunardi S., Jamieson N.B., Lim S.Y., Griffiths K.L., Carvalho-Gaspar M., Al-Assar O., Yameen S., Carter R.C., McKay C.J., Spoletini G., D'Ugo S., Silva M.A., Sansom O.J., Janssen K.P., Muschel R.J., and Brunner T.B.. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget. 5 (2014), 11064-11080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30]. Li C., Wang Z., Liu F., Zhu J., Yang L., Cai G., Zhang Z., Huang W., Cai S., and Xu Y.. CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumour Biology. 35 (2014), 9683-9691. [DOI] [PubMed] [Google Scholar]
  • [31]. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M. AJCC cancer staging man. Springer, NY(2002), pp. 157-164. [Google Scholar]
  • [32]. Miller S., Dykes D., and Polesky H.. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research. 16 (1988), 1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33]. Zhu X., Du L., Feng J., Ling Y., and Xu S.. Clinicopathological and prognostic significance of serum cytokine levels in breast cancer. Clinical Laboratory. 60 (2014), 1145-1151. [DOI] [PubMed] [Google Scholar]
  • [34]. Bronger H., Kraeft S., Schwarz-Boeger U., Cerny C., Stockel A., Avril S., Kiechle M., and Schmitt M.. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Research. 14 (2012), R30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35]. Goldberg-Bittman L., Neumark E., Sagi-Assif O., Azenshtein E., Meshel T., Witz I.P., and Ben-Baruch A.. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunology Letters. 92 (2004), 171-178. [DOI] [PubMed] [Google Scholar]
  • [36]. Haabeth O.A., Lorvik K.B., Hammarstrom C., Donaldson I.M., Haraldsen G., Bogen B., and Corthay A.. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2 (2011), 240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37]. Chew V., Chen J., Lee D., Loh E., Lee J., Lim K.H., Weber A., Slankamenac K., Poon R.T., Yang H., Ooi L.L., Toh H.C., Heikenwalder M., Ng I.O., Nardin A., and Abastado J.P.. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 61 (2012), 427-438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38]. Mlecnik B., Tosolini M., Charoentong P., Kirilovsky A., Bindea G., Berger A., Camus M., Gillard M., Bruneval P., Fridman W.H., Pages F., Trajanoski Z., and Galon J.. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 138 (2010), 1429-1440. [DOI] [PubMed] [Google Scholar]
  • [39]. Li G., Tian L., Hou J.M., Ding Z.Y., He Q.M., Feng P., Wen Y.J., Xiao F., Yao B., Zhang R., Peng F., Jiang Y., Luo F., Zhao X., Zhang L., Zhou Q., and Wei Y.Q.. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res. 11 (2005), 4217-4224. [DOI] [PubMed] [Google Scholar]
  • [40]. Tymoszuk P., Charoentong P., Hackl H., Spilka R., Muller-Holzner E., Trajanoski Z., Obrist P., Revillion F., Peyrat J.P., Fiegl H., and Doppler W.. High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer. 14 (2014), 257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41]. Datta D., Flaxenburg J.A., Laxmanan S., Geehan C., Grimm M., Waaga-Gasser A.M., Briscoe D.M., and Pal S.. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Research. 66 (2006), 9509-9518. [DOI] [PubMed] [Google Scholar]
  • [42]. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., Johnson M.G., Medina J.C., Collins T.L., and Fulton A.M.. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Research. 66 (2006), 7701-7707. [DOI] [PubMed] [Google Scholar]
  • [43]. Ma X., Norsworthy K., Kundu N., Rodgers W.H., Gimotty P.A., Goloubeva O., Lipsky M., Li Y., Holt D., and Fulton A.. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Molecular Cancer Therapeutics. 8 (2009), 490-498. [DOI] [PubMed] [Google Scholar]
  • [44]. Ejaeidi A.A., Craft B.S., Puneky L.V., Lewis R.E., and Cruse J.M.. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis. Experimental and Molecular Pathology. 99 (2015), 163-172. [DOI] [PubMed] [Google Scholar]
  • [45]. Zipin-Roitman A., Meshel T., Sagi-Assif O., Shalmon B., Avivi C., Pfeffer R.M., Witz I.P., and Ben-Baruch A.. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Research. 67 (2007), 3396-3405. [DOI] [PubMed] [Google Scholar]
  • [46]. Chavey C., Bibeau F., Gourgou-Bourgade S., Burlinchon S., Boissiere F., Laune D., Roques S., and Lazennec G.. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Research. 9 (2007), R15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [47]. Cerciat M., Unkila M., Garcia-Segura L.M., and Arevalo M.A.. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia. 58 (2010), 93-102. [DOI] [PubMed] [Google Scholar]
  • [48]. Liu L., Zhao Y., Xie K., Sun X., Jiang L., Gao Y., and Wang Z.. Estrogen inhibits LPS-induced IL-6 production in macrophages partially via the nongenomic pathway. Immunological Investigations. 43 (2014), 693-704. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES